DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20202960

Avapritinib: novel hope for patients with metastatic gist with PDGFRA exon 18 mutation

Sachin Maggo, A. P. Dubey, Pawan Dhull, Nilabh Kumar Singh

Abstract


Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms of the gastrointestinal tract associated with high rates of malignant transformation. The activating mutations in platelet-derived growth factor receptor A (PDGFRA) have been linked to the development of GISTs, and up to approximately 10% of GIST cases involve mutations of this gene. Current treatment options for metastatic GIST are minimal, mainly trusting on tyrosine kinase inhibitors (TKIs) such as Imatinib, Sunitinib and Regorafenib. However, eventually, most patients develop resistance to TKIs, usually due to the acquisition of secondary mutations. Moreover, 5-6% of patients with unresectable of metastatic GIST have the primary PDGFRA D842V mutation, which makes it resistant to all approved treatment options. Avapritinib, a potent and selective TKI of KIT and PDGFRA activation loop mutants. The drug demonstrates anti-tumor activity by inhibiting the autophosphorylation of KIT D816V and PDGFRA D842V, thereby terminating the downstream signalling. The drug is available in oral formulation with a recommended dosage of 300 mg once daily. The onset of Avapritinib is fast, shows rapid absorption and linear pharmacokinetics. Most common adverse reactions seen are edema, fatigue, abdominal pain, and neurocognitive defects. Clinical trials for Avapritinib have been positive, and results suggest that the drug may be a new safe and effective option for metastatic GIST treatment. With Blueprint Medicines having already received US FDA approval in January 2020, Avapritinib may soon be an addition to the mounting armoury of drugs against metastatic GIST harbouring PDGFRA exon 18 mutation.


Keywords


Avapritinib, Metastatic GIST, PDGFRA mutation, Tyrosine kinase inhibitors

Full Text:

PDF

References


Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathology. 2002;10(2):81-9.

Kindblom LG, Remotti HE, Aldenborg F, Kindblom MJM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathology. 1998;152(5):1259.

Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577-80.

Scherubl H, Faiss S, Knoefel WT, Wardelmann E. Management of early asymptomatic gastrointestinal stromal tumors of the stomach. World J Gastrointestinal Endoscopy. 2014;6(7):266.

Scola D, Bahoura L, Copelan A, Shirkhoda A, Sokhandon F. Getting the GIST: a pictorial review of the various patterns of presentation of gastrointestinal stromal tumors on imaging. Abdominal Radiology. 2017;42(5):1350-64.

Vernuccio F, Taibbi A, Picone D, Grutta LL, Midiri M, Lagalla R, et al. Imaging of gastrointestinal stromal tumors: From diagnosis to evaluation of therapeutic response. Anti-cancer Res. 2016;36(6):2639-48.

Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Archives Pathology Laboratory Med. 2006;130(10):1466-78.

Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Molecular cancer. 2018;17(1):58.

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: soft tissue sarcoma (version4.2019).2019. Available at https://www.nccn.org/patients/guidelines/content/PDF/sarcoma-patient.pdf. Accessed on 15 April 2020.

Evans EK, Gardino AK, Kim JL, Hodous BL, Shutes A, Davis A, et al. A precision therapy against cancers driven by KIT/PDGFRA mutations. Science Translational Med. 2017;9(414):1690.

Gebreyohannes YK, Wozniak A, Zhai ME, Wellens J, Cornillie J, Vanleeuw U, et al. Robust activity of avapritinib, potent and highly selective inhibitor of mutated KIT, in patient-derived xenograft models of gastrointestinal stromal tumors. Clin Cancer Res. 2019;25(2):609-18.

Blueprint Medicines Corporation. Ayvakit (avapritinib): US prescribing information; 2020. Available at https://www.accessdata.fda.gov/drugsa tfda_docs/label/2020/212608s000lbl.pdf. Accessed on 15 April 2020.

US Food and Drug Administration. FDA approves avapritinib for gastrointestinal stromal tumor with a rare mutation; 2020. Available at https://www.fda.g-ov/news-events/press-announc-ements/fda-approves-first-targeted-therapy-treat-rare-mutation-patients-gastrointestinal-stromal-tumors. Accessed on 15 April 2020.

Blueprint Medicines. Blueprint Medicines announces FDA approval of AYVAKIT™ (avapritinib) for the treatment of adults with unresectable or metastatic PDGFRA Exon 18 mutant gastrointestinal stromal tumor; 2020. Available at http://ir.blueprintmedic-ines.com/news-releases/news-release-details/blue-print-medicines-announces-fda-approval-ayvakittm-avapritinib. Accessed on 15 April 2020.

United States Securities and Exchange Commission. Form 8-K; 2020. Available at http://ir.blueprint-medicines.com/static-files/760ac82a-c1ad-4d52-bcba-b3bd3bdb6310. Accessed on 15 April 2020.

Dhillon S. Avapritinib: First Approval. Drugs. 2020;25:1-7.

Wu CP, Lusvarghi S, Wang JC, Hsiao SH, Huang YH, Hung TH, et al. Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines. Molecular Pharmaceutics. 2019;16(7):3040-52.

Blueprint Medicines Corporation. Ayvakit (avapritinib): US prescribing information; 2020. Available at https://www.accessdata.fda.gov/dr-ugsatfda_docs/label/2020/212608s000lbl.pdf. Accessed on 15 April 2020.

Heinrich M, Jones R, Mehren VM. Clinical response to avapritinib by RECIST and Choi Criteria in ≥4th Line and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST) (oral presentation). In: Connective Tissue Oncology Society annual meeting; 2019. Available at https://www.blueprintmedicines. com/wp-content/uploads/2019/11/Blueprint-Medic-ines-CTOS-2019-Avapritinib-GIST-Clinical-Respon-se-RECIST-Choi-Criteria-Presentation.pdf. Accessed on 15 April 2020.

Heinrich MC, Jones RL, Mehren VM, Bauer S, Kang YK, Schoffski P, et al. Clinical activity of avapritinib in≥ fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST). (abstract no. 11022 and poster). J Clin Oncol Conf. 2019;37(15).

Bauer S, George S, Kang YK, Tap WD, Zhou T, Picazio N, et al. Voyager: an open-label, randomized, phase III study of avapritinib vs regorafenib in patients (pts) with locally advanced (adv) metastatic or unresectable gastrointestinal stromal tumour (GIST). Annals Oncology. 2018;29:595.

Joseph CP, Abaricia SN, Angelis MA, George S, Jones RL, Kang YK, et al. Avapritinib for the Treatment of GIST: Analysis of Efficacy, Safety, and Patient Management Strategies at the Recommended Phase 2 Dose; ‎2020.